NAS:BMRN (USA) Also trade in: Austria Germany UK

Biomarin Pharmaceutical Inc

$ 88.71 0 (0%)
On watch
Volume: 1,590,789 Avg Vol (1m): 1,228,943
Market Cap $: 15.89 Bil Enterprise Value $: 15.83 Bil
P/E (TTM): 0.00 P/B: 5.39
Earnings Power Value -12.37
Net Current Asset Value 2.35
Tangible Book 12.64
Projected FCF -7.72
Median P/S Value 101.1
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 7/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 1.07
Cash-To-Debt ranked lower than
78.66% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
BMRN: 1.07
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.12, Med: 1.14, Max: 10000
Current: 1.07
0.12
10000
Equity-to-Asset 0.66
Equity-to-Asset ranked lower than
57.40% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
BMRN: 0.66
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -0.66, Med: 0.62, Max: 0.97
Current: 0.66
-0.66
0.97
Debt-to-Equity 0.28
Debt-to-Equity ranked lower than
62.00% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
BMRN: 0.28
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -3.98, Med: 0.41, Max: 19.12
Current: 0.28
-3.98
19.12
Debt-to-EBITDA -58.91
Debt-to-EBITDA ranked lower than
94.39% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
BMRN: -58.91
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -2025.17, Med: -5.09, Max: 22.12
Current: -58.91
-2025.17
22.12
Piotroski F-Score 5
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 6.45
DISTRESS
GREY
SAFE
Beneish M-Score -2.34
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -4.17%
WACC 10.61%

Profitability & Growth : 5/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -12.06
Operating Margin ranked higher than
65.53% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
BMRN: -12.06
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -31.63, Med: -14.97, Max: 5.06
Current: -12.06
-31.63
5.06
Net Margin % -5.90
Net Margin ranked higher than
68.31% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
BMRN: -5.9
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -56.43, Med: -15.04, Max: 54.7
Current: -5.9
-56.43
54.7
ROE % -3.08
ROE ranked higher than
74.32% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
BMRN: -3.08
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -24.39, Med: -7.99, Max: 39.6
Current: -3.08
-24.39
39.6
ROA % -1.97
ROA ranked higher than
76.38% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
BMRN: -1.97
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -16.26, Med: -4.87, Max: 18.88
Current: -1.97
-16.26
18.88
ROC (Joel Greenblatt) % -7.74
ROC (Joel Greenblatt) ranked higher than
77.51% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
BMRN: -7.74
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -89.83, Med: -12.24, Max: 5.59
Current: -7.74
-89.83
5.59
3-Year Total Revenue Growth Rate 18.80
3-Year Revenue Growth Rate ranked higher than
70.20% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
BMRN: 14.8
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -10.4, Med: 13.75, Max: 97.3
Current: 14.8
-10.4
97.3
3-Year Total EBITDA Growth Rate 54.20
3-Year EBITDA Growth Rate ranked lower than
100.00% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
BMRN: 55.9
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: -46.2, Max: 55.9
Current: 55.9
0
55.9
3-Year EPS w/o NRI Growth Rate 25.60
3-Year EPS w/o NRI Growth Rate ranked higher than
54.26% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
BMRN: 25.6
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -25.9, Max: 62
Current: 25.6
0
62

» BMRN's 30-Y Financials

Financials (Next Earnings Date: 2019-08-02)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:BMRN

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:INCY XBRU:UCB OCSE:NZYM B HKSE:02269 HKSE:01177 NAS:SGEN XKRX:207940 OCSE:GEN NAS:IONS NAS:ALNY NAS:MRNA NAS:SRPT NAS:SAGE NAS:BLUE XKRX:068270 SZSE:000661 NAS:JAZZ NAS:TECH HKSE:06160 NAS:NBIX
Traded in other countries BM8.Germany 0HNC.UK
Address 770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme and Vimizim independently. BioMarin markets Kuvan--to treat the rare metabolic disorder PKU--in the U.S., and recently reacquired international rights for Kuvan and PKU drug candidate pegvaliase from Merck KGaA. BioMarin expanded its pipeline with acquisitions in 2010 (LEAD Therapeutics and Zystor) and 2015 (Prosensa).

Ratios

Current vs industry vs history
Forward PE Ratio 114.94
Forward P/E ranked lower than
89.61% of 77 companies
in the Biotechnology industry.
Industry Max: 769.23, Med: 28.41, Min: 3.89
BMRN: 114.94
Ranked among companies with meaningful Forward P/E only.
N/A
PB Ratio 5.39
PB Ratio ranked lower than
65.80% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
BMRN: 5.39
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 3.67, Med: 5.82, Max: 16.77
Current: 5.39
3.67
16.77
PS Ratio 10.39
PS Ratio ranked lower than
51.24% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
BMRN: 10.39
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 3.38, Med: 11.84, Max: 27.08
Current: 10.39
3.38
27.08
Price-to-Operating-Cash-Flow 2063.02
Price-to-Operating-Cash-Flow ranked lower than
100.00% of 210 companies
in the Biotechnology industry.
Industry Max: 23050, Med: 29.99, Min: 0.04
BMRN: 2063.02
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 19.75, Med: 227.23, Max: 43300
Current: 2063.02
19.75
43300
EV-to-EBIT -145.67
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
BMRN: -145.67
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -17265.1, Med: -64.6, Max: 5182.8
Current: -145.67
-17265.1
5182.8
EV-to-EBITDA -1116.82
EV-to-EBITDA ranked lower than
95.02% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
BMRN: -1116.82
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -26007, Med: -79.65, Max: 1043.5
Current: -1116.82
-26007
1043.5
EV-to-Revenue 10.42
EV-to-Revenue ranked higher than
52.92% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
BMRN: 10.42
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 3.3, Med: 11.9, Max: 27.8
Current: 10.42
3.3
27.8
Current Ratio 3.83
Current Ratio ranked lower than
65.46% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
BMRN: 3.83
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.9, Med: 6, Max: 18.94
Current: 3.83
0.9
18.94
Quick Ratio 2.76
Quick Ratio ranked lower than
68.25% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
BMRN: 2.76
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.82, Med: 5.06, Max: 18.77
Current: 2.76
0.82
18.77
Days Inventory 570.10
Days Inventory ranked lower than
94.39% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
BMRN: 570.1
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 420.4, Med: 543.07, Max: 627.16
Current: 570.1
420.4
627.16
Days Sales Outstanding 94.57
Days Sales Outstanding ranked lower than
71.11% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
BMRN: 94.57
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 67.66, Med: 78.96, Max: 86.7
Current: 94.57
67.66
86.7
Days Payable 254.26
Days Payable ranked higher than
78.36% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
BMRN: 254.26
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 25.74, Med: 259.21, Max: 430.52
Current: 254.26
25.74
430.52

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -3.10
3-Year Share Buyback Rate ranked higher than
73.63% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
BMRN: -3.1
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -32.6, Med: -8.85, Max: -3.1
Current: -3.1
-32.6
-3.1

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 7.02
Price-to-Tangible-Book ranked lower than
68.12% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
BMRN: 7.02
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 2.13, Med: 7.53, Max: 116.7
Current: 7.02
2.13
116.7
Price-to-Median-PS-Value 0.88
Price-to-Median-PS-Value ranked lower than
54.42% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
BMRN: 0.88
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.34, Med: 1.4, Max: 12.77
Current: 0.88
0.34
12.77
Earnings Yield (Joel Greenblatt) % -0.69
Earnings Yield (Greenblatt) ranked higher than
75.67% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
BMRN: -0.69
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -5.7, Med: -0.8, Max: 3.7
Current: -0.69
-5.7
3.7

More Statistics

Revenue (TTM) (Mil) $ 1,518.51
EPS (TTM) $ -0.51
Beta 1.4
Volatility % 25.66
52-Week Range $ 79.13 - 106.74
Shares Outstanding (Mil) 179.07

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 5
Positive ROA N
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N